Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
07/17/2025
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Sleep Apnea, Obstructive
Register for Updates
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428
Recruiting
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT04372108
Recruiting
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: NMCP, Portsmouth, Virginia
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725
Recruiting
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/16/2025
Locations: Lysosomal Rare Disorders Research and Treatment Center, Fairfax, Virginia
Conditions: Niemann-Pick Type C Disease
Register for Updates
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543
Recruiting
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/16/2025
Locations: Lysosomal Rare Disorders Research and Treatment Center, Fairfax, Virginia
Conditions: Gangliosidoses, GM2, Gangliosidosis, GM1
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT06899217
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Manassas Clinical Research Center, Manassas, Virginia
Conditions: Idiopathic Gastroparesis
Register for Updates
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
NCT06533865
Recruiting
The goal of this study is to determine whether romosozumab will improve bone density in girls and women with functional hypothalamic amenorrhea (cessation of the menstrual period due to intense exercise, stress, or an eating disorder) who have low bone density. Participants will be randomly assigned to receive romosozumab or placebo for 6 months. All participants will receive one IV infusion of zoledronate at the 6 month visit. All participants will also receive transdermal estradiol and cyclic... Read More
Gender:
FEMALE
Ages:
Between 14 years and 30 years
Trial Updated:
07/16/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: FHA (Functional Hypothalamic Amenorrhea)
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Site 12, Blacksburg, Virginia
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554
Recruiting
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Research Site 1108-0, Fairfax, Virginia
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: NEXT Oncology Virginia, Fairfax, Virginia
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934
Recruiting
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Norfolk, Virginia
Conditions: Eosinophilic Granulomatosis With Polyangiitis
Register for Updates